“We believe TQS-168 represents a new class of treatment for ALS patients and these data paint a compelling picture which shows, in this preclinical model, a potential advance over approved ...

In vitro, TQS-168 also shows specific immunomodulatory effects in cell lines and white blood cells from patients with ALS,” said Jonas Hannestad, MD, PhD, Chief Medical Officer and Head of R&D ...